7 years ago

NuVision Biotherapies Secures £500K Funding for Wound-Healing Therapies

  • NuVision Biotherapies, a Nottingham, UK-based regenerative medicine company, raised £500k in funding from Mercia Fund Managers, angel investors and the University of Nottingham

  • NuVision develops wound-healing therapies using amniotic tissue, and its first product, Omnigen®, is designed for use in eye surgery

  • The company is also developing OmniLenz®, a bespoke contact lens, and exploring other wound care applications, including a clinical study starting in May to treat diabetic foot ulcers.

      • ProblemHealthcare

      "Millions of people worldwide suffer from sight loss caused by wounds that don't heal properly. Traditional treatments are often ineffective and can lead to further complications."

      Solution

      "NuVision Biotherapies has developed a revolutionary wound-healing therapy using amniotic tissue, a natural source of regenerative properties. Their Omnigen® product acts as a biological bandage, promoting healing and reducing the risk of sight loss. They've also created OmniLenz®, a contact lens that delivers the regenerative therapy without surgery."

      Covered on